Norwegian Targovax ASA has given an update of its immunononcology and pancreatic cancer clinical pipeline at ChinaBio Conference in Suzhou. 

Genomic DNA from 5 mg mouse tails each was purified using the Echolution Tissue DNA Micro Kit (BE) and a common Silica kit (Q) and used in qPCR reactions (HOX D9 Amplicon) in dilutions as indicated. The table insert shows the resulting Ct values and the difference by which the Echolution DNA template was detected earlier. (Picture © BioEcho Life Sciences GmbH)

BioEcho GmbH develops kits for the isolation and processing of DNA and RNA with a rapidly expanding portfolio. With expertise and passion, we overcome the limitations of common nucleic acid extraction with pioneering methods such as the proprietary Echolution single-step technology.

Matilda Bingham

Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.

British drug maker AstraZeneca has failed to expand the reach of  its combo of PD-1/CTLA4 checkpoint blockers Durvalumab/Tremelimumab. The approved second-line NSCLC treatment missed to prolong progression-free and overall survival in patients with low PD-L1 expression.

Redx Pharma announced today that it has appointed Lisa Anson as Chief Executive Officer (CEO) and to its Board of Directors. Lisa will take up both roles on 1 June 2018. At that time Iain Ross, currently Executive Chairman, will revert to being Non-Executive Chairman.

Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018.  

Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018.  

Dr. Frank Rijsberman at GBS2018. Picture © BIOCOM AG

Researchers at the Universities of Dundee and Newcastle have identified a previously unknown target for the breast cancer drug palbociclib, which can be used to identify treatment responders. 

EB_Spring_2018_BSP_Sterile_Suite_4_intro_tg.jpg

Poor aseptic practices can rapidly ruin market supply of products outsourced for production. This year, Celltrion came under fire from FDA inspectors. At the end of January, the producer received a warning letter affecting the production of Inflectra biosimilar infliximab-dyyb (CT- P13) co-marketed with Pfizer. In mid-February, the FDA added a warning concerning rituximab and trastuzumab biosimilars produced for Teva, as well as for its fast-track migraine mAb fremanezumab.